Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + carboplatin + paclitaxel
- Development stage
- Phase 4
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a pharmaceutical combination consisting of **pembrolizumab** (a humanized monoclonal antibody targeting the programmed death-1 (PD-1) receptor), **carboplatin** (a platinum-based chemotherapeutic agent), and **paclitaxel** (a microtubule-stabilizing agent). Pembrolizumab enhances anti-tumor immune responses by blocking PD-1-mediated inhibition of T-cell activity. Carboplatin induces cytotoxicity via DNA crosslinking, leading to apoptosis in rapidly dividing cells. Paclitaxel disrupts microtubule function, inhibiting cell division and inducing apoptosis. This combination is FDA-approved for first-line therapy in metastatic squamous non-small cell lung cancer (NSCLC), primary advanced or recurrent endometrial carcinoma, and is in phase IV trials for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)[1][3][4].
- Brand names
- Keytruda + carboplatin + paclitaxel
- Other names
- pembrolizumab + carboplatin + paclitaxel
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on pembrolizumab + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + carboplatin + paclitaxel.